Cancer Genetics Inc

Cancer Genetics — Merger or Acquisition (January 2021)

15 slides from Cancer Genetics's merger presentation, Jan 8, 2021

  1. Slide 1: Disrupting Drug Discovery

    Slide 1: Disrupting Drug Discovery

    CANCER GENETICS INCORPORATED Company Presentation Q1 2021 Disrupting Drug Discovery Integrating Novel Human Spheroid Biology & Data Science Technologies with IND-Enabling Expertise CHESS StemMonix

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    SAFE HARBOR Additional Information about the Proposed Merger and Where to Find It In connection with the proposed Merger between Cancer Genetics (“CGIX") and Stemonix (the “Merger”), CGIX and Stemonix intend to file relevant materials with the Securities and Exchange Commission, or the SEC, includin

  3. Slide 3: Defining a New Approach

    Slide 3: Defining a New Approach

    DEFINING A L New Approach lels for predicting drug efficacy DATA SCIENCE capabilities bring human data to the have underperformed EARLIEST stages of the R&D process and OPTIMIZE THERAPEUTIC EFFICACY & SAFETY Stemonix has created HIGHLY FUNCTIONAL HUMAN spheroids (organ-like models) at SCALE Human ne

  4. Slide 4: Strategic Value Proposition

    Slide 4: Strategic Value Proposition

    Strategic Value Proposition Human-First Drug Discovery Engine: Discovery Engine Industrialized Human Spheroids (Discovery) Data Science Machine Learning Global Pharma Partners GSIBES no STEMONIX CGIX-vivoPharm Cancer Big Data Tumor Line Library Global Partners Efficacy & Safety Data Late Stage Precl

  5. Slide 5: Value Throughout Preclinical Discovery

    Slide 5: Value Throughout Preclinical Discovery

    Value Throughout Preclinical Discovery From ID to IND Early Discovery Platform Preclin. Studies (ADME-Tox) Target ID & Validation Lead Identification Lead Optimization Human iPSC- Assay Development Target-to-Hit & Screening GLP Studies Spheroids Phenotypic Hit-to-Lead Screening + Efficacy/Toxicity +

  6. Slide 6: Global Reach

    Slide 6: Global Reach

    Global Reach Minneapolis, MN Spheroid Production New Jersey 8 Munich, Germany ige) - HQ yject Management, we Marketing Hershey, PA San Diego, CA In vivo Testing Drug Discovery Victoria South Australia Safety & Toxicology Analytical CHESS StemMonix

  7. Slide 7: Discovery In Action

    Slide 7: Discovery In Action

    Discovery In Action Highly-scalable platform for early discovery, pre-clinical, and pharmacology provides guidance, preparation of samples, and clinical trial design +. CNS, CARDIAC AND ['@p } ONCOLOGY STUDIES 25 & TRIALS* BY THE NUMBERS ** CNS and Cardiac are from StemoniX and Oncology are from viv

  8. Slide 8: Proven Team Led By Passion

    Slide 8: Proven Team Led By Passion

    Proven Team Led By Passion Jay Roberts, MBA Ping Yeh, MS MBA Robert Petcavich, PhD Chief Executive Officer Chief Innovation Officer Interim Chief Science Officer Cofounder/CEO of StemoniX and nanotechnologist Cofounder/CSO of Stemonix 30+ years healthcare executive leader 30 year experienced Senior

  9. Slide 9: Convergence Of Biology and Computing

    Slide 9: Convergence Of Biology and Computing

    Convergence Of Biology and Computing Industrialized Highly-Functional AnalytiX ™ Software Technologies Human Spheroids Data Science, Analytics, ML Prioritize the Most Effective Compounds Rank-ordered Compound Listing Target | Drug | Recovery (%) > Drugs rank-ordered by parameter > Example from recen

  10. Slide 10: Human Disease Models and Capabilities

    Slide 10: Human Disease Models and Capabilities

    Human Disease Models and Capabilities Human First Discovery AlAssisted De-risked Platform Assay Phenotypic Lead ” Menor sie aos Bese Model Development | Development | Screening Ce ROnienceton Selection Studies CDKL5 Deficiency Disorder oEach microOrgan Cancer microBrain‘ (GBM/Breast Mets) Neuro-Sphe

  11. Slide 11: Biopharma Relationships

    Slide 11: Biopharma Relationships

    Biopharma Relationships + Large and small molecule drug discovery Partnering with 7 of the Top 10 * Custom model development global biopharma companies + Patient-derived/genetically engineered iPSC lines . . i ina2 4st Neurospheroid' Technology nT) Ue LeeMUe) a Teicha ily Evaluated within the IQ Con

  12. Slide 12: Seeding & Monetizing Partnerships

    Slide 12: Seeding & Monetizing Partnerships

    Seeding & Monetizing Partnerships Representative z ee as Market Deals Single Partner Lifetime Value nts + Royalty Potential) License Out * Clinical assets / models Hemoshear & Takeda (Upfronts + $470M) Leveraged IP { i | 1 * Internal Drug | i i Validate: mEScONEnY Evotec & Celgene gs Manufacture i 6

  13. Slide 13: A Human First Approach

    Slide 13: A Human First Approach

    A Human First Approach Benefits of Incorporating Human Insights into Traditional Drug Discovery De-risks Human relevant in vitro screening and in silico investigation allows for forecasting of therapeutic success prior to clinic and results in superior tox & efficacy Optimizes Human disease models m

  14. Slide 14: Transformational Strategy

    Slide 14: Transformational Strategy

    Transformational Strategy Human-First Drug Stemonix er) Discovery & Development Engine: O .@ i iti Where Scientific * Vertically Integrated > Predictive of Where sient Insights Clinical Success Pw, a pharm partners of Success ¢ Software-accelerated ad Development > faster Bash ito Digital Meets Mark

  15. Slide 15: Stemonix

    Slide 15: Stemonix

    Stemonix CANCER GENETICS INCORPORATED Investor Contact: ® Jennifer K. Zimmons. Ph.D. Investor Relations Zimmons International Communications, Inc. Email: jzimmons@zimmonsic.com Phone: +1.917.214.3514

Source: SEC EDGAR · 425 filed Jan 8, 2021

More decks from Cancer Genetics Inc